Yajin Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yajin Chen has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Botao An
The Second Affiliated Hospital of Harbin Medical University 3 Department of Hepatic Surgery Harbin, China
11 shared publications - Jinhong Chen
Hepatobiliary Surgery, Department of General Surgery, Huashan Hospital and Cancer Metastasis Institute, Fudan University, Shanghai, China
11 shared publications - Lei Zhang
Department of Hepatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
11 shared publications - Qi Li
The First Affiliated Hospital of Xi’an Jiaotong University 4 Department of Hepatobiliary Surgery Xi’an, China
11 shared publications - Sheng Tai
Department of Hepatic Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China
11 shared publications - Yan Geng
Huashan Hospital 5 Department of General Surgery Fudan University, Shanghai, China
11 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Reagents and antibodies used in the study.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Reagents and antibodies used in the study.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Baseline characteristics of the entire cohort.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Baseline characteristics of the entire cohort.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Proportional hazards assumptions checked by schoenfeld residuals.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Proportional hazards assumptions checked by schoenfeld residuals.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Purpose:Nonmetastatic tumor-draining lymph nodes (TDLNs−) are central to initiating and sustaining antitumor immunity. The impact of their surgical removal on immunotherapy efficacy in recurrent biliary tract cancer remains unclear. We investigated the effect of TDLNs− dissection extent on treatment outcomes in this population.Experimental Design:This real-world study retrospectively analyzed clinical and survival data from 101 patients with recurrent biliary tract cancer who received immunotherapy across five Chinese hospitals (2018–2023). Patients were stratified by extent of TDLNs− dissection (≤6 vs. >6). Multiplex immunofluorescence (mIF) analysis of lymph node immune microenvironments was performed in a representative subset of patients (n = 20) from Sun Yat-sen Memorial Hospital.Results:Patients with ≤6 TDLNs− dissected (n = 59) achieved significantly longer progression-free survival (PFS) than those with >6 dissected (n = 42; HR, 0.48; 95% confidence interval, 0.31–0.73; P = 0.001), although there was no statistical difference in overall survival. The mIF staining analysis revealed that TDLNs− contained higher densities of TCF-1+PD-1−CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells and lower proportions of FOXP3+CD4+ regulatory T cells and TCF-1−PD-1+CD69+CD8+ terminally exhausted T cells compared with metastatic TDLNs (TDLNs+). Among immunotherapy responders, TDLNs− exhibited greater TCF-1+PD-1−CD8+ T-cell and CD11c+ cell densities than those in nonresponders. Importantly, a higher proportion of TCF-1+PD-1−CD8+ T cells in TDLNs− correlated with improved PFS, whereas extensive dissection of TDLNs− diminished this benefit.Conclusions:Excessive removal of TDLNs− compromises the efficacy of immunotherapy in recurrent biliary tract cancer. A selective lymphadenectomy approach that prioritizes clearance of TDLNs+ while preserving TDLNs− may optimize outcomes for patients receiving postoperative immunotherapy.See related commentary by Vonderheide, p. 2326
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Purpose:Nonmetastatic tumor-draining lymph nodes (TDLNs−) are central to initiating and sustaining antitumor immunity. The impact of their surgical removal on immunotherapy efficacy in recurrent biliary tract cancer remains unclear. We investigated the effect of TDLNs− dissection extent on treatment outcomes in this population.Experimental Design:This real-world study retrospectively analyzed clinical and survival data from 101 patients with recurrent biliary tract cancer who received immunotherapy across five Chinese hospitals (2018–2023). Patients were stratified by extent of TDLNs− dissection (≤6 vs. >6). Multiplex immunofluorescence (mIF) analysis of lymph node immune microenvironments was performed in a representative subset of patients (n = 20) from Sun Yat-sen Memorial Hospital.Results:Patients with ≤6 TDLNs− dissected (n = 59) achieved significantly longer progression-free survival (PFS) than those with >6 dissected (n = 42; HR, 0.48; 95% confidence interval, 0.31–0.73; P = 0.001), although there was no statistical difference in overall survival. The mIF staining analysis revealed that TDLNs− contained higher densities of TCF-1+PD-1−CD8+ tumor-specific memory T cells and CD11c+ conventional dendritic cells and lower proportions of FOXP3+CD4+ regulatory T cells and TCF-1−PD-1+CD69+CD8+ terminally exhausted T cells compared with metastatic TDLNs (TDLNs+). Among immunotherapy responders, TDLNs− exhibited greater TCF-1+PD-1−CD8+ T-cell and CD11c+ cell densities than those in nonresponders. Importantly, a higher proportion of TCF-1+PD-1−CD8+ T cells in TDLNs− correlated with improved PFS, whereas extensive dissection of TDLNs− diminished this benefit.Conclusions:Excessive removal of TDLNs− compromises the efficacy of immunotherapy in recurrent biliary tract cancer. A selective lymphadenectomy approach that prioritizes clearance of TDLNs+ while preserving TDLNs− may optimize outcomes for patients receiving postoperative immunotherapy.See related commentary by Vonderheide, p. 2326
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Forest plots of PFS by subgroup for the TDLNs− ≤6 group versus the TDLNs− >6 group.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Forest plots of PFS by subgroup for the TDLNs− ≤6 group versus the TDLNs− >6 group.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Distribution of dissected TDLN counts.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Distribution of dissected TDLN counts.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Validation of the prognostic threshold for TDLNs− and assessment of the model robustness.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Validation of the prognostic threshold for TDLNs− and assessment of the model robustness.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Immunotherapy efficacy in patients with recurrent BTC.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Immunotherapy efficacy in patients with recurrent BTC.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Bootstrap distribution of the optimal cutoff value for dissected TDLNs−.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Bootstrap distribution of the optimal cutoff value for dissected TDLNs−.
- Open Access
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Representativeness of study participants.
- 15 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer
Representativeness of study participants.